Stock 1099 SINOPHARM GROUP CO. LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sinopharm Group Co. Ltd.

Equities

1099

CNE100000FN7

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-04-26 am EDT 		5-day change 1st Jan Change
21.55 HKD -0.92% Intraday chart for Sinopharm Group Co. Ltd. +8.40% +5.38%
Apr. 26 Central Bank, Tech Outlooks Lift Major Asian Stock Markets MT
Apr. 16 Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 75,452 49,504 43,125 54,681 58,004 62,251 - -
Enterprise Value (EV) 1 91,399 63,204 63,166 64,207 58,004 65,785 53,111 61,814
P/E ratio 12.1 x 6.87 x 5.55 x 6.42 x 6.41 x 6.34 x 5.79 x 5.26 x
Yield 2.36% 4.35% 5.43% 4.68% - 4.81% 5.26% 5.73%
Capitalization / Revenue 0.18 x 0.11 x 0.08 x 0.1 x 0.1 x 0.1 x 0.09 x 0.08 x
EV / Revenue 0.21 x 0.14 x 0.12 x 0.12 x 0.1 x 0.1 x 0.07 x 0.08 x
EV / EBITDA 5.09 x 3.21 x 2.67 x 2.59 x 2.35 x 2.47 x 1.83 x 1.95 x
EV / FCF 6.57 x -13.8 x 9.72 x 3.47 x - 5.74 x 5.54 x 4.77 x
FCF Yield 15.2% -7.24% 10.3% 28.8% - 17.4% 18.1% 21%
Price to Book 1.59 x 0.88 x 0.7 x 0.8 x - 0.75 x 0.67 x 0.6 x
Nbr of stocks (in thousands) 2,967,629 3,118,654 3,120,656 3,120,656 3,120,656 3,120,656 - -
Reference price 2 25.42 15.87 13.82 17.52 18.59 19.95 19.95 19.95
Announcement Date 3/30/20 3/21/21 3/20/22 3/26/23 3/24/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 425,273 456,415 521,051 552,148 596,570 651,835 710,621 773,759
EBITDA 1 17,950 19,667 23,634 24,769 24,639 26,669 29,072 31,711
EBIT 1 16,137 17,760 19,712 20,604 20,209 23,514 25,741 28,318
Operating Margin 3.79% 3.89% 3.78% 3.73% 3.39% 3.61% 3.62% 3.66%
Earnings before Tax (EBT) 1 13,760 15,598 17,003 18,564 19,512 21,350 23,390 25,730
Net income 1 6,253 7,187 7,759 8,526 9,054 9,827 10,774 11,894
Net margin 1.47% 1.57% 1.49% 1.54% 1.52% 1.51% 1.52% 1.54%
EPS 2 2.100 2.310 2.490 2.730 2.900 3.145 3.445 3.790
Free Cash Flow 1 13,909 -4,574 6,501 18,481 - 11,465 9,594 12,961
FCF margin 3.27% -1% 1.25% 3.35% - 1.76% 1.35% 1.68%
FCF Conversion (EBITDA) 77.49% - 27.51% 74.61% - 42.99% 33% 40.87%
FCF Conversion (Net income) 222.46% - 83.79% 216.77% - 116.67% 89.05% 108.97%
Dividend per Share 2 0.6000 0.6900 0.7500 0.8200 - 0.9592 1.049 1.144
Announcement Date 3/30/20 3/21/21 3/20/22 3/26/23 3/24/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2023 S2 2024 S1
Net sales 1 223,608 203,765 252,650 249,120 271,931 261,472 290,676 18,687 155,433 300,950 144,969 150,650 295,619 321,924
EBITDA - - - - - - - - - - - - - -
EBIT 1 - - - 8,772 10,940 9,057 11,547 - 5,895 10,869 5,937 4,691 10,628 11,691
Operating Margin - - - 3.52% 4.02% 3.46% 3.97% - 3.79% 3.61% 4.1% 3.11% 3.6% 3.63%
Earnings before Tax (EBT) 1 - - - - - - - - 5,228 8,866 4,161 6,485 - -
Net income - - - - - - - 362.2 2,514 4,104 1,752 - - -
Net margin - - - - - - - 1.94% 1.62% 1.36% 1.21% - - -
EPS - - - - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 3/30/20 8/23/20 3/21/21 8/22/21 3/20/22 8/29/22 3/26/23 4/17/23 8/27/23 8/27/23 10/30/23 3/24/24 3/24/24 -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 15,947 13,699 20,041 9,526 - 3,534 - -
Net Cash position 1 - - - - - - 9,140 438
Leverage (Debt/EBITDA) 0.8884 x 0.6966 x 0.848 x 0.3846 x - 0.1325 x - -
Free Cash Flow 1 13,909 -4,574 6,501 18,481 - 11,465 9,594 12,961
ROE (net income / shareholders' equity) 13.9% 13.9% 13.1% 13.1% - 12% 12% 11.6%
ROA (Net income/ Total Assets) 2.47% 2.47% 2.4% 2.44% - 2.45% 2.49% 2.49%
Assets 1 252,832 290,559 323,331 350,101 - 401,329 433,198 477,351
Book Value Per Share 2 16.00 18.10 19.80 21.80 - 26.70 29.70 33.20
Cash Flow per Share 2 6.320 3.590 2.980 6.720 - 6.040 3.430 6.080
Capex 1 4,868 4,585 2,807 2,482 - 3,328 3,173 3,309
Capex / Sales 1.14% 1% 0.54% 0.45% - 0.51% 0.45% 0.43%
Announcement Date 3/30/20 3/21/21 3/20/22 3/26/23 3/24/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Sinopharm Group Co. Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
19.95 CNY
Average target price
25.06 CNY
Spread / Average Target
+25.63%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+5.38% 8.59B
MCKESSON CORPORATION Stock McKesson Corporation
+17.35% 71.39B
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
+2.39% 25.1B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+6.69% 8.19B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-20.96% 7.91B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+0.49% 4.54B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+17.12% 4.31B
EBOS GROUP LIMITED Stock EBOS Group Limited
-3.38% 3.93B
GALENICA AG Stock Galenica AG
-2.61% 3.86B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+22.08% 3.64B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. 1099 Stock
  4. Financials Sinopharm Group Co. Ltd.